Lasix (furosemide), the widely prescribed loop diuretic, is not routinely recommended during pregnancy but is used when serious maternal conditions demand it. A meta-analysis covering nearly 7,000 neonates exposed to diuretics in utero found no increased risk of birth defects, growth restriction, or other major adverse outcomes, and more recent registry data from the European Society of Cardiology echoes that finding. Still, furosemide crosses the placenta, reaches the fetus, and can affect amniotic fluid volume, so its use is reserved for situations where the benefit to the mother clearly outweighs the theoretical risks to the baby.
When Lasix Is Actually Prescribed During Pregnancy
Most pregnant people will never need furosemide. The drug is not given for the ankle swelling and mild fluid retention that are a normal part of pregnancy. Instead, it tends to appear in emergency or high-acuity settings where the mother’s heart or lungs are in trouble. The classic scenario is acute pulmonary edema, where fluid floods the lungs and breathing becomes dangerously compromised. This can happen in pregnant women with pre-existing heart disease, severe valve problems like mitral stenosis, or in cases of preeclampsia that progress to congestive heart failure.
A published case of preeclampsia complicated by congestive heart failure and pulmonary edema illustrates how Lasix fits into that emergency picture. The patient received intravenous furosemide at 60 mg initially, then 40 mg three times daily, tapered as she stabilized. That aggressive dosing, combined with blood pressure medication and an emergency cesarean delivery, was credited with saving both mother and baby.1Medicover Journal of Medicine. A case of preeclampsia presenting with congestive cardiac failure with pulmonary edema In situations like these, withholding the diuretic would pose a far greater danger than using it.
Women with chronic heart failure who become pregnant sometimes continue a diuretic they were already taking before conception. This is a separate scenario from the emergency use just described, and it raises different questions about first-trimester exposure and long-term fetal effects. We will get to those questions shortly.
Does Furosemide Cross the Placenta?
Yes, and fairly efficiently. In a study of 18 pregnant women given oral furosemide on the day of delivery, researchers found substantial drug concentrations in both umbilical cord vein plasma and amniotic fluid. By about eight to ten hours after the dose, the ratio between the mother’s blood levels and the cord blood levels approached one-to-one, meaning the fetus was exposed to concentrations roughly equal to the mother’s.2PubMed. Placental transfer of furosemide
This is worth knowing because it means furosemide is not acting only on the mother’s kidneys. The drug reaches the fetal kidneys too, and the immature fetal kidney handles it differently than an adult kidney would. That said, reaching the fetus and harming the fetus are not the same thing. The safety question hinges on what the drug actually does once it gets there.
What the Large-Scale Safety Data Show
The most reassuring evidence comes from pooled data. A meta-analysis encompassing nearly 7,000 neonates exposed to diuretics during pregnancy did not find an increased risk of birth defects, fetal growth restriction, thrombocytopenia, or neonatal diabetes.3PubMed Central. Use of diuretics during pregnancy That is a large enough sample to detect anything but a very rare problem, and it included various types of diuretics, furosemide among them.
Data from the European Society of Cardiology’s Registry of Pregnancy and Cardiac Disease (ROPAC) adds a more targeted look at first-trimester exposure, which is the window when major organ formation happens and birth defect risk is highest. In that registry, the rate of the composite outcome including fetal and neonatal congenital anomalies was 5.8% among women who used diuretics in the first trimester, compared with 5.2% among women who never used diuretics during pregnancy. That difference was not statistically significant. Even after adjusting for other variables, first-trimester diuretic use was not associated with congenital anomalies.4European Journal of Heart Failure. Diuretics in Pregnancy: Data from the ESC Registry of Pregnancy and Cardiac Disease (ROPAC) – Section: Results
There is, however, a counterpoint worth mentioning. A large-scale analysis of the FDA Adverse Event Reporting System (FAERS) database flagged a signal for dysmorphism associated with furosemide, along with statins and spironolactone.5PubMed. Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database – Section: RESULTS FAERS data is useful for raising flags, but it is a spontaneous-reporting system, not a controlled study. Reports are submitted voluntarily, confounding factors are rarely accounted for, and the women taking furosemide during pregnancy almost always have serious underlying heart disease that itself carries risks for the fetus. So this signal does not overturn the controlled data showing no clear increase in birth defects, but it does explain why researchers continue to study the question rather than closing the book on it.
Effects on Amniotic Fluid
This is where the practical concern during pregnancy gets more concrete. Since furosemide crosses the placenta and acts on fetal kidneys, it can reduce fetal urine output, and fetal urine is a major contributor to amniotic fluid in the second and third trimesters. In theory, aggressive diuretic dosing could lower amniotic fluid volume to problematic levels.
A case report of a woman with severe mitral stenosis who developed pulmonary edema and received high-dose furosemide documented exactly this: she developed transient oligohydramnios, meaning amniotic fluid dropped below normal range temporarily.6PubMed Central. Amniotic fluid volume changes in response to frusemide induced maternal fluid shifts The key word is “transient.” Once the high dosing was scaled back, fluid levels recovered. But the case underscores why women receiving furosemide during pregnancy need close monitoring of amniotic fluid, especially at higher doses.
Interestingly, an older study looking at women with preeclampsia found that furosemide treatment had no significant effect on amniotic fluid volume in that group.7PubMed. Furosemide action on the creatinine concentration of amniotic fluid This might reflect lower doses, shorter treatment courses, or the particular physiology of preeclampsia. Either way, the picture that emerges is dose-dependent: standard therapeutic doses seem to be tolerated without major amniotic fluid problems, while sustained high doses warrant more careful surveillance.
Why Lasix Is Not the Answer for Normal Pregnancy Swelling
A common misconception is that the puffy ankles and swollen fingers of a healthy pregnancy could or should be treated with a diuretic. They should not. Physiological edema in pregnancy results from an expansion of blood volume that is actually necessary for adequate blood flow to the placenta and fetus. Shrinking that blood volume with a diuretic does not fix a problem; it creates one. The concern, raised by clinicians for decades, is that diuretics reduce plasma volume and could decrease placental perfusion, meaning less blood flow reaching the baby.8PubMed Central. Use of diuretics during pregnancy – Section: Abstract
In the specific conditions where furosemide is genuinely indicated, like pulmonary edema or decompensated heart failure, the mother’s expanded fluid volume has become dangerous to her. That changes the calculus entirely. But for routine swelling, elevation, compression stockings, and staying well hydrated are the appropriate approaches. No diuretic belongs in that picture.
Concerns About the Immature Neonatal Kidney
The neonatal kidney is structurally and functionally immature, and furosemide exposure, whether from maternal dosing during pregnancy or from direct administration to a newborn, can stress it in particular ways. A review of adverse drug effects on the immature kidney noted that furosemide use in neonates has been associated with hypercalciuria (excessive calcium in the urine), nephrocalcinosis (calcium deposits in kidney tissue), and secondary hyperparathyroidism.9Karger Publishers. Adverse Effects of Drugs on the Immature Kidney These effects are more relevant when furosemide is given directly to premature neonates in intensive care, but the finding highlights why clinicians are cautious about fetal exposure as well.
There has also been a longstanding question about whether furosemide affects closure of the ductus arteriosus, a blood vessel that normally shuts down shortly after birth. Older concerns suggested furosemide might keep it open, leading to patent ductus arteriosus (PDA), a condition that sometimes requires medical or surgical intervention in premature infants. More recent studies have softened that worry. A large retrospective analysis of hospitalized very low birth weight infants found that furosemide exposure was actually associated with decreased odds of needing PDA treatment, not increased odds.10PubMed Central. Association between Furosemide Exposure and Patent Ductus Arteriosus in Hospitalized Very Low Birth Weight Infants – Section: Results A separate comprehensive retrospective study found no correlation between furosemide exposure and spontaneous ductal closure, and the cumulative dose had minimal impact on whether or when the ductus closed.11PubMed Central. Furosemide and Ductus Arteriosus Closure in Very-Low-Birth-Weight Preterm Infants: A Comprehensive Retrospective Study – Section: Results So while the concern is frequently mentioned in older references, the more recent data does not support a meaningful connection.
Hearing Loss Concerns in Premature Infants
Furosemide is known to be potentially ototoxic, meaning it can harm the structures of the inner ear. At high intravenous doses in adults, this effect is well-documented and usually reversible. In premature infants, whose hearing pathways are still developing, the worry has been that even standard doses might cause lasting sensorineural hearing loss. This concern applies both to direct neonatal dosing and, at least theoretically, to fetal exposure from maternal treatment.
A systematic review that gathered all available trials and observational studies on this question found no evidence that furosemide exposure increases the risk of sensorineural hearing loss or nephrocalcinosis in premature infants. The reviewers rated the overall strength of evidence as low, largely because most studies failed to account for confounding factors, meaning premature infants who receive furosemide tend to be sicker overall, making it hard to isolate the drug’s effect.12PubMed Central. Association between furosemide in premature infants and sensorineural hearing loss and nephrocalcinosis: a systematic review – Section: Abstract
A separate study looking specifically at prolonged furosemide exposure and newborn hearing screens found that the rate of abnormal hearing screens in the furosemide-exposed group was slightly higher than in the never-exposed group, but the difference was not statistically significant.13Early Human Development. Prolonged furosemide exposure and risk of abnormal newborn hearing screen in premature infants – Section: RESULTS The researchers concluded that additional studies with post-discharge audiology follow-up are needed. In practical terms, the ototoxicity risk from maternal furosemide use during pregnancy appears low, but it is not fully ruled out, and premature infants who were exposed may benefit from closer hearing follow-up.
How Pregnancy Changes Furosemide’s Behavior in the Body
Pregnancy alters the way your body handles many medications, and furosemide is no exception. A pharmacokinetic study comparing pregnant and non-pregnant women found that pregnant women had significantly lower drug exposure, lower peak blood levels, and excreted less of the total dose in urine. Their non-kidney clearance of the drug was significantly increased. In other words, pregnant women clear furosemide faster and absorb less of it, which may explain why higher or more frequent doses are sometimes needed to achieve the same therapeutic effect.14PubMed Central. Lack of Modulation of In Vivo Activity of Organic Anion Transporters 1 and 3 in Pregnancy Using Furosemide as a Probe
What made this study particularly interesting was the finding about kidney transporters. The researchers had expected to find that the kidney’s organic anion transporters (the molecular machinery responsible for actively pumping furosemide into the urine) would be more active during pregnancy, as had been shown for other drugs that use the same pathway. Instead, they found that transporter activity was unchanged. The lower overall drug exposure appeared to stem from changes in absorption and non-kidney metabolism rather than from the kidneys pumping the drug out faster. For clinicians, this means that dose adjustments in pregnancy cannot simply be extrapolated from how other drugs behave. Furosemide has its own pharmacokinetic personality during pregnancy.
What About Breastfeeding?
Many women who needed furosemide during pregnancy or around delivery wonder whether they can continue it while nursing. Furosemide does pass into breast milk, but in very small amounts. The bigger practical concern is actually not toxicity to the infant but the effect on milk supply. Diuretics reduce total body fluid, and because breast milk production depends on adequate hydration and blood flow to the mammary glands, aggressive diuretic therapy can decrease milk output. Women who need ongoing furosemide while breastfeeding should work closely with their prescriber to use the lowest effective dose and stay well hydrated. Most guidelines consider furosemide compatible with breastfeeding when clinically necessary, but the potential impact on supply is real and worth discussing.
Postpartum Use for Hypertensive Disorders
Furosemide is also used in the period immediately after delivery in women who had preeclampsia or other hypertensive disorders during pregnancy. The goal in this setting is to speed up recovery of blood pressure to normal levels. After delivery, the expanded blood volume of pregnancy needs to contract, and in women whose blood pressure was dangerously high, helping that process along with a short course of furosemide can shorten the time it takes for blood pressure to normalize. This postpartum application carries fewer fetal concerns because the baby has already been delivered, though it can affect breastfeeding as mentioned above. Randomized trials have explored this specific use, examining whether postpartum furosemide accelerates blood pressure recovery compared with expectant management alone.15Ovid / PubMed Central / American Heart Association. Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial
For women who had severe preeclampsia, the days after delivery can involve lingering high blood pressure, significant fluid retention, and occasionally worsening symptoms before things start to improve. A brief course of furosemide during this window is a different risk-benefit situation from using it at 20 weeks of gestation. The fetus is no longer in the equation, and the mother’s body needs help returning to its pre-pregnancy state. Clinicians tend to be much more liberal with furosemide in this context.
Why Some Old Concerns Persist Despite Reassuring Data
If you search for furosemide in pregnancy, you will find sources that range from “absolutely avoid” to “reasonably safe when indicated.” Part of this inconsistency traces back to animal studies from decades ago that showed adverse fetal effects at very high doses in rodents, a finding that does not translate directly to human therapeutic doses but nonetheless shaped early prescribing caution. Another part stems from the legitimate physiological concern about plasma volume reduction, which is real but mainly applies to inappropriate use for normal edema rather than to emergency or cardiac-indicated use.
The FAERS signal for dysmorphism also keeps the conversation alive, even though controlled registry data like ROPAC has not confirmed an association.16European Journal of Heart Failure. Diuretics in Pregnancy: Data from the ESC Registry of Pregnancy and Cardiac Disease (ROPAC) – Section: Results And there is a reasonable argument that because pregnant women who take furosemide almost always have serious heart disease, separating the drug’s effects from the underlying disease’s effects is genuinely difficult. A woman with decompensated heart failure has reduced cardiac output, abnormal oxygen delivery, and hemodynamic instability, all of which independently threaten the fetus. Attributing any adverse outcome to the diuretic rather than the disease requires carefully controlled studies that are ethically challenging to conduct.
The practical upshot is that furosemide remains classified as a pregnancy drug to use only when clearly needed, which is a sensible position given the available evidence. It is not contraindicated outright, and the large-scale data is more reassuring than many clinicians and patients realize. But it is also not a drug anyone prescribes casually during pregnancy, and that caution is appropriate given the dose-dependent effects on amniotic fluid and the still-incomplete understanding of how the immature fetal kidney responds to it.